Pimecrolimus Topical Dosage
This dosage information may not include all the information needed to use Pimecrolimus Topical safely and effectively. See additional information for Pimecrolimus Topical.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Atopic Dermatitis
Apply a thin layer to the affected area twice daily and rub in gently and completely.
Usual Pediatric Dose for Atopic Dermatitis
<3 months: Safety and efficacy have not been established
3 months to 2 years: Not approved by the FDA for use in this age group
>= 2 years: Apply a thin layer to the affected area twice daily and rub in gently and completely
Renal Dose Adjustments
There are no data on dosing adjustments of pimecrolimus topical in patients with renal dysfunction; however, due to its minimal systemic bioavailability, no significant adjustments are expected.
Liver Dose Adjustments
There are no data on dosing adjustments of pimecrolimus topical in patients with liver dysfunction; however, due to its minimal systemic bioavailability, no significant adjustments are expected.
Occlusive dressings should not be used.
Caregivers and patients should wash their hands after applying pimecrolimus.
The patient should be reevaluated if symptoms do not improve or worsen after 6 weeks of treatment.
Pimecrolimus topical is not approved by the FDA for treatment of children less than 2-years-old due to higher incidence of infections reported in this age group, and the unknown long-term effect of pimecrolimus topical on the developing immune system of infants and young children.
There are rare reports of malignancy (such as skin and lymphoma) in patients treated with calcineurin inhibitors, including pimecrolimus; however, a causal relationship has not been established. It is recommended to avoid long-term treatment with these agents, to limit application to areas of involvement with atopic dermatitis, and to avoid use in the treatment of unapproved indications.
There are no data on the hemodialysis or peritoneal dialysis clearance of pimecrolimus; however, due to its minimal systemic bioavailability, no significant adjustments are expected.
More about pimecrolimus topical
- Other brands: Elidel